LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function | PNAS
Frontiers | A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)
Figure 1 from Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors. | Semantic Scholar
EpiAxis Therapeutics clinical study validates targeting LSD1 inhibition
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation | Science Advances
LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia
Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors - ScienceDirect
Medicinal chemistry insights in the discovery of novel LSD1 inhibitors | Epigenomics
Summary of LSD1/KDM1A inhibitors in clinical trials and clinical use. a | Download Table
Advances toward LSD1 inhibitors for cancer therapy | Future Medicinal Chemistry
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication | Oncogenesis
Histone lysine specific demethylase 1 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D0MD00141D
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy | Leukemia
Summary of LSD1/KDM1A inhibitors in clinical trials and clinical use. a | Download Table
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines | PLOS ONE
![PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9fafead40352c90508f95afefb569266941b8712/5-Table1-1.png "PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar")
PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar
Advances toward LSD1 inhibitors for cancer therapy | Future Medicinal Chemistry
Natural products as LSD1 inhibitors for cancer therapy - ScienceDirect
LSD1 inhibitors in clinical trials. (A) Structure of TCP-based... | Download Scientific Diagram
